The UK Medicines & Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Novartis’ Cosentyx (secukinumab) in two types of juvenile idiopathic arthritis (JIA), enthesitis-related arthritis (ERA), and juvenile psoriatic arthritis (JPsA). The drug is approved alone or in combination with methotrexate (MTX) in patients six years and older whose disease has responded inadequately […]
Menu ≡ ╳ 
